KR101033818B1 - 돼지의 알파에스 1 카제인 유전자, 그 프로모터 및 그의 용도 - Google Patents
돼지의 알파에스 1 카제인 유전자, 그 프로모터 및 그의 용도 Download PDFInfo
- Publication number
- KR101033818B1 KR101033818B1 KR1020090058189A KR20090058189A KR101033818B1 KR 101033818 B1 KR101033818 B1 KR 101033818B1 KR 1020090058189 A KR1020090058189 A KR 1020090058189A KR 20090058189 A KR20090058189 A KR 20090058189A KR 101033818 B1 KR101033818 B1 KR 101033818B1
- Authority
- KR
- South Korea
- Prior art keywords
- vector
- casein
- seq
- pig
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010076119 Caseins Proteins 0.000 title claims abstract description 54
- 241000282887 Suidae Species 0.000 title claims description 17
- 239000013598 vector Substances 0.000 claims abstract description 163
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 146
- 239000013604 expression vector Substances 0.000 claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 43
- 241001465754 Metazoa Species 0.000 claims abstract description 41
- 235000018102 proteins Nutrition 0.000 claims abstract description 28
- 235000013336 milk Nutrition 0.000 claims abstract description 18
- 239000008267 milk Substances 0.000 claims abstract description 18
- 210000004080 milk Anatomy 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- 241000282898 Sus scrofa Species 0.000 claims description 66
- 239000002773 nucleotide Substances 0.000 claims description 57
- 125000003729 nucleotide group Chemical group 0.000 claims description 57
- 108050000244 Alpha-s1 casein Proteins 0.000 claims description 52
- 102000009366 Alpha-s1 casein Human genes 0.000 claims description 47
- 230000009261 transgenic effect Effects 0.000 claims description 17
- 241000699670 Mus sp. Species 0.000 claims description 12
- 238000000520 microinjection Methods 0.000 claims description 11
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000012212 insulator Substances 0.000 claims description 8
- 210000001082 somatic cell Anatomy 0.000 claims description 8
- 241000283707 Capra Species 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 210000003101 oviduct Anatomy 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000283923 Marmota monax Species 0.000 claims description 4
- 230000001124 posttranscriptional effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 102000044890 human EPO Human genes 0.000 claims description 3
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 235000020256 human milk Nutrition 0.000 claims 1
- 210000004251 human milk Anatomy 0.000 claims 1
- 102000011632 Caseins Human genes 0.000 abstract description 35
- 239000005018 casein Substances 0.000 abstract description 27
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract description 27
- 235000021240 caseins Nutrition 0.000 abstract description 27
- 108700026220 vif Genes Proteins 0.000 abstract description 3
- -1 promoter Substances 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 128
- 210000004027 cell Anatomy 0.000 description 41
- 238000012163 sequencing technique Methods 0.000 description 33
- 230000003321 amplification Effects 0.000 description 31
- 238000003199 nucleic acid amplification method Methods 0.000 description 31
- 238000000034 method Methods 0.000 description 30
- 101000741052 Sus scrofa Alpha-S1-casein Proteins 0.000 description 28
- 235000013601 eggs Nutrition 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 18
- 238000004925 denaturation Methods 0.000 description 18
- 230000036425 denaturation Effects 0.000 description 18
- 238000012408 PCR amplification Methods 0.000 description 17
- 108091008146 restriction endonucleases Proteins 0.000 description 17
- 239000000523 sample Substances 0.000 description 16
- 229930193140 Neomycin Natural products 0.000 description 15
- 229960004927 neomycin Drugs 0.000 description 15
- 230000035772 mutation Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 208000009889 Herpes Simplex Diseases 0.000 description 7
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- 108020005345 3' Untranslated Regions Proteins 0.000 description 6
- 108020003589 5' Untranslated Regions Proteins 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 241001045988 Neogene Species 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000005075 mammary gland Anatomy 0.000 description 6
- 101150091879 neo gene Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101100333654 Homo sapiens EPO gene Proteins 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 101000756628 Mus musculus Actin, cytoplasmic 1 Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101150047086 arm gene Proteins 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000004216 mammary stem cell Anatomy 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 235000021247 β-casein Nutrition 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- UROVZOUMHNXPLZ-AVGNSLFASA-N His-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 UROVZOUMHNXPLZ-AVGNSLFASA-N 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 235000021249 α-casein Nutrition 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- BGNLUHXLSAQYRQ-FXQIFTODSA-N Ala-Glu-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O BGNLUHXLSAQYRQ-FXQIFTODSA-N 0.000 description 1
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 1
- ZXKNLCPUNZPFGY-LEWSCRJBSA-N Ala-Tyr-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N ZXKNLCPUNZPFGY-LEWSCRJBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- NUBPTCMEOCKWDO-DCAQKATOSA-N Arg-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N NUBPTCMEOCKWDO-DCAQKATOSA-N 0.000 description 1
- VNFWDYWTSHFRRG-SRVKXCTJSA-N Arg-Gln-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O VNFWDYWTSHFRRG-SRVKXCTJSA-N 0.000 description 1
- LXMKTIZAGIBQRX-HRCADAONSA-N Arg-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O LXMKTIZAGIBQRX-HRCADAONSA-N 0.000 description 1
- NNMUHYLAYUSTTN-FXQIFTODSA-N Asn-Gln-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O NNMUHYLAYUSTTN-FXQIFTODSA-N 0.000 description 1
- JREOBWLIZLXRIS-GUBZILKMSA-N Asn-Glu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JREOBWLIZLXRIS-GUBZILKMSA-N 0.000 description 1
- BKDDABUWNKGZCK-XHNCKOQMSA-N Asn-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O BKDDABUWNKGZCK-XHNCKOQMSA-N 0.000 description 1
- AKKUDRZKFZWPBH-SRVKXCTJSA-N Asp-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N AKKUDRZKFZWPBH-SRVKXCTJSA-N 0.000 description 1
- QPDUWAUSSWGJSB-NGZCFLSTSA-N Asp-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N QPDUWAUSSWGJSB-NGZCFLSTSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 241001429175 Colitis phage Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 101100497384 Drosophila melanogaster CASK gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- KZKBJEUWNMQTLV-XDTLVQLUSA-N Gln-Ala-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KZKBJEUWNMQTLV-XDTLVQLUSA-N 0.000 description 1
- PGPJSRSLQNXBDT-YUMQZZPRSA-N Gln-Arg-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O PGPJSRSLQNXBDT-YUMQZZPRSA-N 0.000 description 1
- QBLMTCRYYTVUQY-GUBZILKMSA-N Gln-Leu-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QBLMTCRYYTVUQY-GUBZILKMSA-N 0.000 description 1
- ZVQZXPADLZIQFF-FHWLQOOXSA-N Gln-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 ZVQZXPADLZIQFF-FHWLQOOXSA-N 0.000 description 1
- RLZBLVSJDFHDBL-KBIXCLLPSA-N Glu-Ala-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RLZBLVSJDFHDBL-KBIXCLLPSA-N 0.000 description 1
- ZCOJVESMNGBGLF-GRLWGSQLSA-N Glu-Ile-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZCOJVESMNGBGLF-GRLWGSQLSA-N 0.000 description 1
- WNRZUESNGGDCJX-JYJNAYRXSA-N Glu-Leu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O WNRZUESNGGDCJX-JYJNAYRXSA-N 0.000 description 1
- SYWCGQOIIARSIX-SRVKXCTJSA-N Glu-Pro-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O SYWCGQOIIARSIX-SRVKXCTJSA-N 0.000 description 1
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 1
- XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 1
- BEQGFMIBZFNROK-JGVFFNPUSA-N Gly-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)O BEQGFMIBZFNROK-JGVFFNPUSA-N 0.000 description 1
- ORXZVPZCPMKHNR-IUCAKERBSA-N Gly-His-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CNC=N1 ORXZVPZCPMKHNR-IUCAKERBSA-N 0.000 description 1
- SJLKKOZFHSJJAW-YUMQZZPRSA-N Gly-Met-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)CN SJLKKOZFHSJJAW-YUMQZZPRSA-N 0.000 description 1
- AAXMRLWFJFDYQO-GUBZILKMSA-N His-Asp-Gln Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O AAXMRLWFJFDYQO-GUBZILKMSA-N 0.000 description 1
- SWSVTNGMKBDTBM-DCAQKATOSA-N His-Gln-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SWSVTNGMKBDTBM-DCAQKATOSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- YPWHUFAAMNHMGS-QSFUFRPTSA-N Ile-Ala-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N YPWHUFAAMNHMGS-QSFUFRPTSA-N 0.000 description 1
- PPSQSIDMOVPKPI-BJDJZHNGSA-N Ile-Cys-Leu Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O PPSQSIDMOVPKPI-BJDJZHNGSA-N 0.000 description 1
- FTUZWJVSNZMLPI-RVMXOQNASA-N Ile-Met-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N FTUZWJVSNZMLPI-RVMXOQNASA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- LJHGALIOHLRRQN-DCAQKATOSA-N Leu-Ala-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LJHGALIOHLRRQN-DCAQKATOSA-N 0.000 description 1
- POJPZSMTTMLSTG-SRVKXCTJSA-N Leu-Asn-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N POJPZSMTTMLSTG-SRVKXCTJSA-N 0.000 description 1
- VZBIUJURDLFFOE-IHRRRGAJSA-N Leu-His-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VZBIUJURDLFFOE-IHRRRGAJSA-N 0.000 description 1
- QLDHBYRUNQZIJQ-DKIMLUQUSA-N Leu-Ile-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QLDHBYRUNQZIJQ-DKIMLUQUSA-N 0.000 description 1
- AKVBOOKXVAMKSS-GUBZILKMSA-N Leu-Ser-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O AKVBOOKXVAMKSS-GUBZILKMSA-N 0.000 description 1
- DRCILAJNUJKAHC-SRVKXCTJSA-N Lys-Glu-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DRCILAJNUJKAHC-SRVKXCTJSA-N 0.000 description 1
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 1
- ISHNZELVUVPCHY-ZETCQYMHSA-N Lys-Gly-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O ISHNZELVUVPCHY-ZETCQYMHSA-N 0.000 description 1
- HAUUXTXKJNVIFY-ONGXEEELSA-N Lys-Gly-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAUUXTXKJNVIFY-ONGXEEELSA-N 0.000 description 1
- SPCHLZUWJTYZFC-IHRRRGAJSA-N Lys-His-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O SPCHLZUWJTYZFC-IHRRRGAJSA-N 0.000 description 1
- LNMKRJJLEFASGA-BZSNNMDCSA-N Lys-Phe-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LNMKRJJLEFASGA-BZSNNMDCSA-N 0.000 description 1
- QVTDVTONTRSQMF-WDCWCFNPSA-N Lys-Thr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CCCCN QVTDVTONTRSQMF-WDCWCFNPSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- HSJIGJRZYUADSS-IHRRRGAJSA-N Met-Lys-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HSJIGJRZYUADSS-IHRRRGAJSA-N 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- XWBJLKDCHJVKAK-KKUMJFAQSA-N Phe-Arg-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N XWBJLKDCHJVKAK-KKUMJFAQSA-N 0.000 description 1
- FRMKIPSIZSFTTE-HJOGWXRNSA-N Phe-Tyr-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FRMKIPSIZSFTTE-HJOGWXRNSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- SKICPQLTOXGWGO-GARJFASQSA-N Pro-Gln-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)N)C(=O)N2CCC[C@@H]2C(=O)O SKICPQLTOXGWGO-GARJFASQSA-N 0.000 description 1
- KTFZQPLSPLWLKN-KKUMJFAQSA-N Pro-Gln-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KTFZQPLSPLWLKN-KKUMJFAQSA-N 0.000 description 1
- YXHYJEPDKSYPSQ-AVGNSLFASA-N Pro-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 YXHYJEPDKSYPSQ-AVGNSLFASA-N 0.000 description 1
- DRKAXLDECUGLFE-ULQDDVLXSA-N Pro-Leu-Phe Chemical compound CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O DRKAXLDECUGLFE-ULQDDVLXSA-N 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000021839 RNA stabilization Effects 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101100272807 Rattus norvegicus Btg2 gene Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- YUSRGTQIPCJNHQ-CIUDSAMLSA-N Ser-Arg-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YUSRGTQIPCJNHQ-CIUDSAMLSA-N 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 description 1
- JURQXQBJKUHGJS-UHFFFAOYSA-N Ser-Ser-Ser-Ser Chemical compound OCC(N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CO)C(O)=O JURQXQBJKUHGJS-UHFFFAOYSA-N 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- QGXCWPNQVCYJEL-NUMRIWBASA-N Thr-Asn-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QGXCWPNQVCYJEL-NUMRIWBASA-N 0.000 description 1
- CTONFVDJYCAMQM-IUKAMOBKSA-N Thr-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)N CTONFVDJYCAMQM-IUKAMOBKSA-N 0.000 description 1
- ZQUKYJOKQBRBCS-GLLZPBPUSA-N Thr-Gln-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O ZQUKYJOKQBRBCS-GLLZPBPUSA-N 0.000 description 1
- GDPDVIBHJDFRFD-RNXOBYDBSA-N Trp-Tyr-Tyr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GDPDVIBHJDFRFD-RNXOBYDBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- NOXKHHXSHQFSGJ-FQPOAREZSA-N Tyr-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NOXKHHXSHQFSGJ-FQPOAREZSA-N 0.000 description 1
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 1
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 101150070593 lox gene Proteins 0.000 description 1
- 108010045397 lysyl-tyrosyl-lysine Proteins 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 108010047079 phenylalanyl-leucyl-arginyl-phenylalanine Proteins 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010025826 prolyl-leucyl-arginine Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
| 서열번호 | 염기서열 분석용 프라이머 |
| 20 | 5'-TAACGAATCCAACTAGGAACC-3' |
| 21 | 5'-TCCTTCTCCAACCCTATATTC-3' |
| 22 | 5'-TGAGAGGGGAATAGAAAGAAC-3' |
| 23 | 5'-TATCAATAGGTCTCAGAAGATC-3' |
| 24 | 5'-TAGACTTCGAGTTTGGAGGG-3' |
| 25 | 5'-TATAAGGCACAAATGAGCCCTT-3' |
| 26 | 5'-AAATGCTCAACATCCCTGATTA-3' |
| 27 | 5'-TATTCCGTGTTCATGGATTGG-3' |
| 28 | 5'-AAGTATTCTCCACTGCCTTAC-3' |
| 29 | 5'-TGTGAGTATGGTAGAGAATTT-3' |
| 30 | 5'-CTATTGTGAATAGAGCTGCAAT-3' |
| 31 | 5'-GTGTGAGAGTGTGTACCAGTT-3' |
| 32 | 5'-TGTTCCCTTGTGATATATAGC-3' |
| 33 | 5'-CTTGTTCCCACAGTTCAAATG-3' |
| 34 | 5'-TAGATACCTCCACCAAGAGC-3' |
| 35 | 5'-TTCTCAGGTTTCCTGAGGTG-3' |
| 36 | 5'-GTGCACATTTACATACTGATAG-3' |
| 37 | 5'-ATCATCAATGAACTGAACAGGGT-3' |
| 38 | 5'-TTGAGACCTAAGTCACAGCTA-3' |
| 39 | 5'-TCCATAATAATTTATGTCAAGGG-3' |
| 40 | 5'-TAAGGCAAAATGTGCATGAGTG-3' |
| 프라이머 | 서열번호 | |
| 정방향 4.6kb | 5'-AGGATTACAAGATTGCTGTTGGA-3' | 42 |
| 역방향 4.6kb | 5'-AAAATCGTCAACTACCCTGATTA-3' | 43 |
| 정방향 5.7kb | 5'-AGCTGCAATGAACATGTGGGTG-3' | 44 |
| 역방향 5.7kb | 5'-CACCCACATGTTCATTGCAGCT-3' | 45 |
| 정방향 4.9kb | 5'-CACTCAGTATGAGAGTCTTAG-3' | 46 |
| 역방향 4.9kb | 5'-CTGTTCAGTTCATTGATGATTTC-3' | 47 |
| 정방향 5.4kb | 5'-TTTGGTTCTGCTGTGCCATAA-3' | 48 |
| 역방향 5.4kb | 5'-GTAGAGCTTAGAGTTCAACTC-3' | 49 |
| 정방향 5.3kb | 5'-CACTCAGGATGAGATTCTCTA-3' | 50 |
| 역방향 5.3kb | 5'-AACTGATTGATGACTACTATGTT-3' | 51 |
| 정방향 4.7kb | 5'-AGATCTGACACCTTCTAATTAC-3' | 52 |
| 역방향 4.7kb | 5'-GTGTATTCCTGCACAGCAAC-3' | 53 |
| 정방향 4.4kb | 5'-GTCAAACTGCCTTCTAGAGTC-3' | 54 |
| 역방향 4.4kb | 5'-GTAGACTTATGTGAAGCTCTG-3' | 55 |
| 프라이머 | 서열번호 | |
| 프로모터 증폭용 정방향 프라이머 | 5'-GGATCCGGCTGTCGTTTTGTTATGATT-3' | 56 |
| 프로모터 증폭용 역방향 프라이머 | 5'-CTCGAGAACTAAAAGGCACAGGGAACT-3' | 57 |
| 3'arm 증폭용 정방향 프라이머 | 5'-CTCGAGTTACAATTCAGTGTGGGGAAT-3' | 58 |
| 3'arm 증폭용 역방향 프라이머 | 5'-GCGGCCGCCAGCTTTATTACAGGCAGAGG-3' | 59 |
| 프라이머 | 서열번호 | |
| 1차 포인트 뮤테이션용 정방향 프라이머 | 5'-TATATACTACATCTTCCGGGTCCAATCATCTGTTGATGG-3' | 60 |
| 1차 포인트 뮤테이션용 역방향 프라이머 | 5'-CCATCAACAGATGATTGGACCCGGAAGATGTAGTATATA-3' | 61 |
| 2차 포인트 뮤테이션용 정방향 프라이머 | 5'-AAGACGTGGCTTGGGTCCCACGTTGCTGT-3' | 62 |
| 2차 포인트 뮤테이션용 역방향 프라이머 | 5'-ACAGCAACGTGGGACCCAAGCCACGTCTT-3' | 63 |
| 프라이머 | 서열번호 | |
| hEPO증폭용 정방향 프라이머 | 5'-GGATCCTGTGGTCACCCGGCGCGC-3' | 64 |
| hEPO증폭용 역방향 프라이머 | 5'-GATATCCCATGGGACAGGCTGGCGCT-3' | 65 |
| WPRE증폭용 정방향 프라이머 | 5'-GATATCTCTGTTCCTGTTAATCAACCTC -3' | 66 |
| WPRE증폭용 역방향 프라이머 | 5'-GCGGCCGCGAGCCCGAGGCGAAACAG-3' | 67 |
| 프라이머 | 서열번호 | |
| 프로모터 증폭용 정방향 프라이머 | 5'-GGATCCGGCTGTCGTTTTGTTATGATT-3' | 70 |
| 프로모터 증폭용 역방향 프라이머 | 5'-GGATCCAACTAAAAGGCACAGGGAACT-3' | 71 |
| 3'arm 증폭용 정방향 프라이머 | 5'-GCGGCCGCTTACAATTCAGTGTGGGGAAT-3' | 72 |
| 3'arm 증폭용 역방향 프라이머 | 5'-GCGGCCGCCAGCTTTATTACAGGCAGAGG-3' | 73 |
| 프라이머 | 서열번호 | |
| hEPO 증폭용 일차 정방향 프라이머 | 5'-GTGTTGACAACCATGGGGGTGCACGGTGAGTACTC-3' | 74 |
| hEPO 증폭용 이차 정방향 프라이머 | 5'-GATATCTTTTCTTATATAGGTGTTGACAACCATGGGGG-3' | 75 |
| hEPO 증폭용 역방향 프라이머 | 5'-GAATTCATGGGACAGGCTGGCGCTGA-3' | 76 |
| 프라이머 | 서열번호 | |
| 프로모터 증폭용 정방향 프라이머 | 5'-GTCGACAGCTGCAATGAACATGTGGGTG-3' | 77 |
| 프로모터 증폭용 역방향 프라이머 | 5'-GATATCCAAAATAAAAATTTAGGTCTGACAG-3' | 78 |
| 3'arm 증폭용 정방향 프라이머 | 5'-GCGGCCGCATGGCATATGGAAGTTCCCAGG-3' | 79 |
| 3'arm 증폭용 역방향 프라이머 | 5'-CCGCGGTGGGAACTTCCATATGCCAT-3' | 80 |
| 프라이머 | 서열번호 | |
| EPO 증폭용 정방향 | 5'-CAAGGAGGCCGAGAATATCA-3' | 84 |
| EPO 증폭용 역방향 | 5'-AAGTGTCAGCAGTGATTGTTCG-3' | 85 |
| Neo 증폭용 정방향 | 5'-GCTACCCGTGATATTGCTGAA-3' | 86 |
| Neo 증폭용 역방향 | 5'-CAACACCGTGCGTTTTATTCT-3' | 87 |
| 인간 beta actin 증폭용 정방향 | 5'-CGTGGGCCGCCCTAGGCACCA-3' | 88 |
| 인간 beta actin 증폭용 역방향 | 5'-TTGGCCTTAGGGTTCAGGGGGG-3' | 89 |
| 생쥐 beta actin 증폭용 정방향 | 5'-TGTGATGGTGGGAATGGGTCAG-3' | 90 |
| 생쥐 beta actin 증폭용 역방향 | 5'-TTTGATGTCACGCACGATTTTCC-3' | 91 |
| 프라이머 | 서열번호 | |
| EPO-WPRE 증폭용 정방향 프라이머 | 5'-AACTCTTCCGAGTCTACTCCA-3' | 92 |
| EPO-WPRE 증폭용 역방향 프라이머 | 5'-CTCCTCATAAAGAGACAGCAAC-3' | 93 |
| WPRE-3'arm 증폭용 정방향 프라이머 | 5'-TTCCTGTTAATCAACCTCTGG-3' | 94 |
| WPRE-3'arm 증폭용 역방향 프라이머 | 5'-TACCAAAGGCCATAATTGTGG-3' | 95 |
Claims (25)
- 프로모터, 및 3' UTR 부위를 포함하는 서열번호 1의 염기서열을 갖는 돼지 알파에스 1 카제인 유전자.
- 서열번호 2의 염기서열을 포함하는 돼지 알파에스 1 카제인 유전자 프로모터.
- 서열번호 2의 염기서열, 서열번호 3의 염기서열, 및 서열번호 4의 염기서열 중에서 선택된 하나 이상의 염기서열을 포함하는 발현 벡터.
- 제3항에 있어서, 상기 벡터는 서열번호 5 또는 서열번호 6 중에서 선택된 하나 이상의 염기서열을 추가로 갖는 것인 발현벡터.
- 제3항에 있어서, 상기 벡터는 선택적 표지 유전자, 인슐레이터, 및 WPRE(woodchuck hepatitus virus posttranscriptional regulatory element) 중에서 선택된 하나 이상이 추가된 것인 발현벡터.
- 제5항에 있어서, 상기 벡터는 도 2의 개열지도를 갖는 것인 발현 벡터.
- 제6항에 있어서, 상기 벡터는 기탁번호 KCTC 11324BP로 기탁된 pBC1-pig αS1 casein인 발현 벡터.
- 제3항 내지 제5항 중 어느 한 항에 있어서, 프로모터 염기서열의 3' 쪽으로 목적단백질을 암호화하는 염기서열을 추가로 갖는 발현 벡터.
- 제8항에 있어서, 상기 목적단백질은 인간EPO(erythropoietin)인 발현 벡터.
- 제9항에 있어서, 상기 벡터는 도 3의 개열지도를 갖는 것인 발현 벡터.
- 제10항에 있어서, 상기 벡터는 기탁번호 KCTC 11325BP로 기탁된 pBC1-pig αS1 casein+hEPO-WPRE인 발현 벡터.
- 제4항에 있어서, 상기 발현벡터는 낙인벡터(knock-in vector)인 발현벡터.
- 제12항에 있어서, 상기 낙인벡터는 선별유전자가 추가된 것인 발현 벡터.
- 제13항에 있어서, 상기 낙인벡터는 도 4의 개열지도를 갖는 것인 발현 벡터.
- 제14항에 있어서, 상기 낙인벡터는 기탁번호 KCTC 11326BP로 기탁된 Pig α S1 casein-hEPO knock in인 발현 벡터.
- 제3항 내지 제5항 중 어느 한 항의 발현 벡터를 도입시켜 형질전환시킨 동물의 체세포.
- 제3항 내지 제5항 중 어느 한 항의 발현 벡터가 주입된 동물 수정란.
- 제17항에 있어서, 상기 주입은 미세주입법에 의한 것인 동물 수정란.
- 제17항의 동물 수정란을 이식시켜 얻은 형질전환동물.
- 제19항에 있어서, 상기 형질전환동물은 돼지, 생쥐, 소, 양, 및 염소 중에서 선택된 하나인 형질전환동물.
- 제17항의 동물수정란을 대리모의 난관 내에 이식한 후, 대리모로부터 형질전환동물을 얻고, 상기 형질전환동물의 유즙으로부터 목적단백질을 제조하는 제조방법.
- 제3항 내지 제5항 중 어느 한 항의 발현 벡터를 도입시켜 형질전환시킨 동물의 체세포를 탈핵된 난자에 핵이식하여 만든 동물 수정란.
- 제22항의 수정란을 이식시켜 얻은 형질전환동물.
- 제23항에 있어서, 상기 형질전환동물은 돼지, 생쥐, 소, 양, 및 염소 중에서 선택된 하나인 형질전환동물.
- 제3항 내지 제5항 중 어느 한 항의 발현 벡터를 도입시켜 형질전환된 동물의 체세포를 탈핵된 난자에 핵이식하여 만든 동물 수정란을 대리모 동물에 이식하고, 상기 대리모 동물로부터 형질전환동물을 얻고, 상기 형질전환동물의 유즙으로부터 목적단백질을 생산하는 단계를 포함하는 단백질의 제조방법.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080062765 | 2008-06-30 | ||
| KR20080062765 | 2008-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100003223A KR20100003223A (ko) | 2010-01-07 |
| KR101033818B1 true KR101033818B1 (ko) | 2011-05-13 |
Family
ID=41466443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090058189A Active KR101033818B1 (ko) | 2008-06-30 | 2009-06-29 | 돼지의 알파에스 1 카제인 유전자, 그 프로모터 및 그의 용도 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9738694B2 (ko) |
| EP (1) | EP2305814B1 (ko) |
| JP (1) | JP5507555B2 (ko) |
| KR (1) | KR101033818B1 (ko) |
| CN (1) | CN102124109B (ko) |
| AU (1) | AU2009266603B2 (ko) |
| CA (1) | CA2729625C (ko) |
| WO (1) | WO2010002160A2 (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8420388B2 (en) * | 2008-06-30 | 2013-04-16 | Cho-A Pharm. Co., Ltd. | Gene of porcine beta casein, a promoter of the same and the use thereof |
| CA2854819C (en) | 2011-11-16 | 2022-07-19 | Sangamo Biosciences, Inc. | Modified dna-binding proteins and uses thereof |
| CN102653773B (zh) * | 2012-04-26 | 2015-01-14 | 天津农学院 | 牛乳腺特异性表达载体pBC-αs1及制备方法 |
| KR101938956B1 (ko) | 2016-05-31 | 2019-01-15 | 제주대학교 산학협력단 | 신경세포 특이적으로 발현하는 돼지 Thy1 유전자 프로모터 |
| KR101928659B1 (ko) | 2017-06-19 | 2018-12-13 | 서울대학교병원 | Dna 변형 유도 단백질 복합체 및 이를 암호화하는 유전자를 포함하는 재조합 벡터 |
| CN110257392A (zh) * | 2019-06-28 | 2019-09-20 | 西安医学院 | 转录后水平低氧调控基因、应用及其调控方法 |
| US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
| WO2022072718A1 (en) | 2020-09-30 | 2022-04-07 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5959171A (en) | 1994-08-17 | 1999-09-28 | Pharming B.V. | Method for the production of biologically active polypeptides in a mammal's |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| JPH08507687A (ja) | 1993-03-12 | 1996-08-20 | クレイトン ユニバーシティ | 遺伝子治療用の改良されたベクター |
| US5610053A (en) | 1993-04-07 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells |
| JPH09298981A (ja) * | 1996-05-16 | 1997-11-25 | Y S New Technol Kenkyusho:Kk | トランスジェニックブタ |
| JPH1084981A (ja) * | 1996-07-26 | 1998-04-07 | Y S New Technol Kenkyusho:Kk | 乳腺発現用ベクター |
| KR100232640B1 (ko) | 1997-06-03 | 1999-12-01 | 박호군 | 에리트로포이에틴 (epo)을 생산하는 세포주, 그의 제조방법 및 이를 이용한 epo의 제조방법 |
| US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| KR100434729B1 (ko) | 1998-03-18 | 2004-11-03 | 주식회사 엘지생명과학 | 천연 추출물을 첨가하여 중국햄스터 난소 유래세포에서 에리스로포이에틴의 생산 증대방법 |
| US6436707B1 (en) | 1998-03-27 | 2002-08-20 | Lexicon Genetics Incorporated | Vectors for gene mutagenesis and gene discovery |
| WO1999066054A2 (en) | 1998-06-15 | 1999-12-23 | Genzyme Transgenics Corp. | Erythropoietin analog-human serum albumin fusion protein |
| JP2001197846A (ja) * | 2000-01-18 | 2001-07-24 | Ys New Technology Kenkyusho:Kk | 免疫寛容動物の作製方法 |
| WO2001057079A2 (en) | 2000-01-31 | 2001-08-09 | Pharming Intellectual Property B.V. | C1 inhibitor produced in the milk of transgenic mammals |
| KR100358754B1 (ko) * | 2000-02-14 | 2002-11-07 | 대한민국 | 인간의 조혈촉진제 생산을 위한 형질전환 돼지를 생산하는방법 및 그 형질전환 돼지 |
| AU2002252310A1 (en) * | 2001-03-12 | 2002-09-24 | Stephen P Butler | Transgenic proteins from multi-gene systems, methods, compositions, uses and the like relating thereto |
| CN1283785C (zh) | 2002-05-20 | 2006-11-08 | 上海杰隆生物工程股份有限公司 | 利用转基因动物乳腺生产人促红细胞生成素的方法 |
| CU23102A1 (es) | 2002-10-21 | 2005-12-20 | Ct Ingenieria Genetica Biotech | Método para la producción de proteínas recombinantes en la glándula mamaria de mamíferos no transgénicos |
| ATE384790T1 (de) | 2002-11-04 | 2008-02-15 | Cho A Pharm Co Ltd | Uroplakin-ii-promotor aus schwein und verfahren zur herstellung nützlicher proteine unter verwendung des promotors |
| KR100552634B1 (ko) | 2002-11-04 | 2006-02-20 | 조아제약주식회사 | 돼지의 유로플라킨 ⅱ 유전자의 프로모터 및 이를 이용한유용단백질의 생산 방법 |
| KR20040101793A (ko) | 2003-05-27 | 2004-12-03 | 재단법인서울대학교산학협력재단 | 사람 에리트로포이에틴을 생산하는 형질전환 복제소 및이의 생산 방법 |
| JP2005160359A (ja) * | 2003-12-01 | 2005-06-23 | Rikogaku Shinkokai | Sineの挿入多型を指標とした鯨種判別方法 |
| US7667089B2 (en) | 2004-04-09 | 2010-02-23 | National Chung Hsing University | Transgenic mammal secreting B-domain deleted human FVII in its milk |
| EA016039B1 (ru) * | 2005-05-02 | 2012-01-30 | Милеутис Лтд. | Способы ухода за лактирующими животными и фармацевтические композиции, используемые для их осуществления |
| US7902352B2 (en) * | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
| KR100769291B1 (ko) | 2006-02-13 | 2007-10-24 | 조아제약주식회사 | 유선 특이적 인간 에리트로포이에틴 발현 벡터, 이를이용한 형질전환 동물 및 이를 이용한 인간에리트로포이에틴의 생산 방법 |
| CA2685900A1 (en) | 2006-05-04 | 2007-11-15 | Wayne State University | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
| WO2008075911A1 (en) * | 2006-12-20 | 2008-06-26 | Avixgen Inc. | Vector for expressing nc protein of hiv and method for producing nc protein using the same |
| JP2010535496A (ja) | 2007-08-08 | 2010-11-25 | チョ−エー・ファーム・カンパニー・リミテッド | 乳腺特異的ヒトエリトロポエチン発現ベクター、これを用いた形質転換動物及びこれを用いたヒトエリトロポエチンの産生方法 |
| US8420388B2 (en) | 2008-06-30 | 2013-04-16 | Cho-A Pharm. Co., Ltd. | Gene of porcine beta casein, a promoter of the same and the use thereof |
-
2009
- 2009-06-29 EP EP09773696.1A patent/EP2305814B1/en active Active
- 2009-06-29 KR KR1020090058189A patent/KR101033818B1/ko active Active
- 2009-06-29 US US12/737,319 patent/US9738694B2/en not_active Expired - Fee Related
- 2009-06-29 AU AU2009266603A patent/AU2009266603B2/en not_active Ceased
- 2009-06-29 CA CA2729625A patent/CA2729625C/en active Active
- 2009-06-29 JP JP2011516140A patent/JP5507555B2/ja not_active Expired - Fee Related
- 2009-06-29 CN CN200980126110XA patent/CN102124109B/zh not_active Expired - Fee Related
- 2009-06-29 WO PCT/KR2009/003516 patent/WO2010002160A2/ko not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5959171A (en) | 1994-08-17 | 1999-09-28 | Pharming B.V. | Method for the production of biologically active polypeptides in a mammal's |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2729625C (en) | 2016-02-02 |
| US9738694B2 (en) | 2017-08-22 |
| WO2010002160A9 (ko) | 2010-05-06 |
| JP5507555B2 (ja) | 2014-05-28 |
| AU2009266603A1 (en) | 2010-01-07 |
| AU2009266603B2 (en) | 2013-01-24 |
| EP2305814A4 (en) | 2011-12-28 |
| CN102124109B (zh) | 2013-10-16 |
| CN102124109A (zh) | 2011-07-13 |
| WO2010002160A2 (ko) | 2010-01-07 |
| JP2011526495A (ja) | 2011-10-13 |
| CA2729625A1 (en) | 2010-01-07 |
| EP2305814B1 (en) | 2015-08-05 |
| KR20100003223A (ko) | 2010-01-07 |
| WO2010002160A3 (ko) | 2010-07-01 |
| US20110239314A1 (en) | 2011-09-29 |
| EP2305814A2 (en) | 2011-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101033818B1 (ko) | 돼지의 알파에스 1 카제인 유전자, 그 프로모터 및 그의 용도 | |
| KR101999410B1 (ko) | 염색체 랜딩 패드 및 관련된 용도 | |
| AU2022200784B2 (en) | Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception | |
| CN113373178A (zh) | 一种tlr8基因人源化动物模型的构建方法及应用 | |
| CA2426669A1 (en) | .alpha.1-3 galactosyltransferase gene and promoter | |
| WO2004003156A2 (en) | Il-21 as a regulator of immunoglobin production | |
| KR101033819B1 (ko) | 돼지의 베타 카제인 유전자, 그 프로모터 및 그의 용도 | |
| Zhang et al. | The goat β-casein/CMV chimeric promoter drives the expression of hLF in transgenic goats produced by cell transgene microinjection | |
| AU2019339404B2 (en) | Complement factor h gene knockout rat as a model of C3 glomerulopathy | |
| US20020194635A1 (en) | Transgenic animals resistant to transmissible spongiform encephalopathies | |
| KR20080032139A (ko) | S1―5를 포함하는 단백질 제제 | |
| KR20210129083A (ko) | 유전적으로 변형된 나트륨 채널을 갖는 설치류 및 이의 사용 방법 | |
| CN112715436A (zh) | 一种百褶裙泰狮金鱼的批量繁育方法 | |
| US20040265806A1 (en) | Position-independent and tissue specific expression of a transgene in milk of transgenic animals | |
| CN108135151A (zh) | 前列腺癌的啮齿动物模型 | |
| CN112813107B (zh) | 一种龙睛百褶裙泰狮金鱼的创制方法 | |
| US20020142378A1 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
| KR20070030947A (ko) | S1―5를 함유하는 단백질 제재 | |
| CN114835798A (zh) | Cd36基因人源化非人动物的构建方法及应用 | |
| JP2003274961A (ja) | 乳腺発現用ベクター | |
| KR19980073991A (ko) | 한국산 재래용 산양의 베타카제인 프로모터를 이용한 유선조직특이적 발현 시스템 | |
| KR20150047670A (ko) | 돼지의 유청 단백질 유전자 프로모터를 이용한 유선 발현 시스템 | |
| WO2001000860A2 (en) | Prolactin-inducible mammary specific promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20090629 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20110427 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20110502 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20110502 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20140107 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140107 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20160108 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160108 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20170109 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170109 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20180108 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180108 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20190108 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190108 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20200108 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200108 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210108 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230121 Start annual number: 13 End annual number: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240418 Start annual number: 14 End annual number: 14 |